news
Novel oral therapy shows potential in plaque psoriasis
"Development of a novel oral therapy that specifically targets IL-23R could potentially change the treatment paradigm” in moderate-to-severe plaque psoriasis (PsO), stated a Janssen R&D VP.
List view / Grid view
Janssen Research and Development
news
Janssen investigational treatment for schizophrenia shows positive efficacy, delays relapse
20 March 2014 | By Johnson & Johnson
Independent data monitoring committee recommends halting trial and unblinding data based on treatment efficacy...
news
Independent data monitoring committee recommends early stopping of Phase 3 study of Ibrutinib
7 January 2014 | By Johnson & Johnson
Janssen Research & Development, LLC today announced the early stopping of PCYC-1112-CA, the Phase 3 study of IMBRUVICA™ (ibrutinib) in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), based on the recommendation of an Independent Data Monitoring Committee (IDMC), which concluded that the study showed a significant…
news
New data at American Society of Hematology (ASH) Annuaul Meeting will offer important insights into safe and efficacious use of XARELTO®
3 December 2013 | By
XARELTO® is the most prescribed novel oral anticoagulant in the U.S. Market today...
news
New two-year results show SIMPONI® ARIA™ (GOLIMUMAB) for infusion inhibited radiographic progression in patients with active rheumatoid arthritis
28 October 2013 | By Johnson & Johnson
Nearly 70 percent of patients receiving SIMPONI ARIA at two years demonstrated ACR 20 response...
news
FDA Advisory Committee recommends approval of Simeprevir for combination treatment of genotype 1 chronic hepatitis C in adult patients
24 October 2013 | By Johnson & Johnson
Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration voted unanimously to recommend approval of the investigational protease inhibitor simeprevir...
news
Simeprevir Data from COSMOS study in Hepatitis C Patients accepted as late-breaking presentation at the annual meeting of the American Association for the Study of Liver Diseases (AASLD)
8 October 2013 | By Johnson & Johnson
Simeprevir works by blocking the protease enzyme that enables the hepatitis C virus to replicate in host cells...
news
Latest Phase 3 Results demonstrate safety profile of INVOKANA® (canagliflozin) as add-on therapy in the treatment of Type 2 Diabetes
24 September 2013 | By Janssen Research & Development, LLC
In patients inadequately controlled on metformin and a sulfonylurea, study results suggest canagliflozin improves glycemic control and was generally well tolerated, compared to placebo...
news
Simultaneous applications submitted to FDA and EMA for siltuximab for the treatment of MCD, a rare blood disorder
3 September 2013 | By Johnson & Johnson
“We’re proud of our work on siltuximab. As a rare disease with a small patient population, MCD is an area of significant unmet need”
news
Janssen Research & Development announces establishment of global cross-pharmaceutical clinical trial Investigator Databank
15 November 2012 | By Janssen Global Services
Lilly and Merck are first to join Janssen in this pre-competitive initiative to increase efficiencies in clinical trials...
news
Pfizer announces co-primary clinical endpoints not met in second Phase 3 Bapineuzumab Study
6 August 2012 | By Pfizer
Bapineuzumab IV Phase 3 program discontinued...
